genetically modified autologous CD34+ hematopoietic stem cells (Expression/Emory)

N/A

Report date: 2025/01/26 15:38:42

Base Information

Drug Namegenetically modified autologous CD34+ hematopoietic stem cells (Expression/Emory)
Drug Alias NameCD68-ET3-LV CD34+ cell therapygenetically modified autologous CD34+ hematopoietic stem cells (Lentigen/Expression/Emory)ET3 (Expression)LG-889
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionBlood coagulation stimulants
TargetsUpdating
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLentigen Technology Inc
China Registration ClassN/A

Develop Information

Active CompaniesExpression Therapeutics LlcEmory University
Inactive CompaniesLentigen Technology Inc
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A